TIME LIMITS RESTRICTION IN GERMANY
Author(s)
Thivolet M1, Soussi I2, Kornfeld A1, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3University Claude Bernard Lyon I, Lyon, France
OBJECTIVES In Germany, with the introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in January 1st
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PHP160
Topic
Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Reimbursement & Access Policy
Disease
Multiple Diseases